- Home
- NNY vs ALDX Comparison
NNY vs ALDX Comparison
Compare NNY & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- ALDX
- Stock Information
- Founded
- NNY 1987
- ALDX 2004
- Country
- NNY United States
- ALDX United States
- Employees
- NNY N/A
- ALDX N/A
- Industry
- NNY Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- NNY Finance
- ALDX Health Care
- Exchange
- NNY Nasdaq
- ALDX Nasdaq
- Market Cap
- NNY 156.0M
- ALDX 133.7M
- IPO Year
- NNY N/A
- ALDX 2014
- Fundamental
- Price
- NNY $8.27
- ALDX $2.18
- Analyst Decision
- NNY
- ALDX Strong Buy
- Analyst Count
- NNY 0
- ALDX 2
- Target Price
- NNY N/A
- ALDX $9.50
- AVG Volume (30 Days)
- NNY 50.9K
- ALDX 1.5M
- Earning Date
- NNY 01-01-0001
- ALDX 05-20-2025
- Dividend Yield
- NNY 4.04%
- ALDX N/A
- EPS Growth
- NNY N/A
- ALDX N/A
- EPS
- NNY N/A
- ALDX N/A
- Revenue
- NNY N/A
- ALDX N/A
- Revenue This Year
- NNY N/A
- ALDX N/A
- Revenue Next Year
- NNY N/A
- ALDX N/A
- P/E Ratio
- NNY N/A
- ALDX N/A
- Revenue Growth
- NNY N/A
- ALDX N/A
- 52 Week Low
- NNY $7.58
- ALDX $1.14
- 52 Week High
- NNY $8.87
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- NNY 57.61
- ALDX 35.31
- Support Level
- NNY $8.13
- ALDX $1.90
- Resistance Level
- NNY $8.40
- ALDX $2.89
- Average True Range (ATR)
- NNY 0.08
- ALDX 0.22
- MACD
- NNY 0.03
- ALDX 0.09
- Stochastic Oscillator
- NNY 69.05
- ALDX 28.28
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.